Receptor Integral To Or Derived From A Lymphocytic Or Lymphocytic-like Cell (e.g., Nk Cell, Etc.) Patents (Class 424/144.1)
  • Patent number: 11867696
    Abstract: The present disclosure provides high-performance immunoreagents for use in a variety of immunologic assays and other related techniques. The immunoreagents comprise a primary antibody and a bridging antigen, wherein the bridging antigen is recognized by a detectable secondary antibody with high affinity. Also provided are compositions comprising panels of immunoreagents specific for multiple different target antigens and compositions comprising pairs of primary immunoreagents and their complementary detectable secondary antibodies. The paired primary immunoreagents and secondary antibodies are useful in a variety of immunologic assays, particularly in highly multiplexed assays, where the structure of the bridging antigen is varied in tandem with variation in the detectable secondary antibody, such that a multiplicity of immunoreagents are provided that are capable of simultaneously detecting a multiplicity of target antigens in a single assay.
    Type: Grant
    Filed: February 6, 2016
    Date of Patent: January 9, 2024
    Assignee: CELL IDX, INC.
    Inventor: David A. Schwartz
  • Patent number: 11859208
    Abstract: This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: January 2, 2024
    Assignee: Emory University
    Inventors: Edmund Waller, Anna Morris, Christopher Petersen, Jian-Ming Li, Reema Panjwani, Jingxia Li
  • Patent number: 11845794
    Abstract: Disclosed herein are chimeric antigen receptors (CAR) that can specifically recognize tumor-associated antigens (TAA) on multiple myeloma (MM) cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with MM that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: December 19, 2023
    Assignee: Ohio State Innovation Foundation
    Inventors: Jianhua Yu, Craig Hofmeister, Jianhong Chu
  • Patent number: 11612659
    Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: March 28, 2023
    Inventors: Claudia Mueller, Matthias Willmann
  • Patent number: 11479580
    Abstract: Polypeptides belonging to the family of late proteins of the cornified envelope (LCE), fragments of the polypeptide, isolated nucleotide sequences encoding the polypeptides, and cosmetic and/or pharmaceutical compositions containing such polypeptides are described. The polypeptides have cosmetic and/or therapeutic use to reinforce the barrier function of the epidermis, prevent and/or treat the signs of skin dryness and prevent and/or treat disorders of the barrier function or the weakening of the epidermis.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: October 25, 2022
    Inventors: Nathalie Jonca, Eve Toulza, Gaelle Saintigny, Guy Serre, Marina Weber Vivat
  • Patent number: 11479605
    Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: October 25, 2022
    Assignee: Nykode Therapeutics ASA
    Inventors: Pier Adelchi Ruffini, Bjarne Bogen, Agnete Brunsvik Fredriksen
  • Patent number: 11464800
    Abstract: The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: October 11, 2022
    Assignee: Immatics US, Inc.
    Inventors: Mamta Kalra, Zoe Coughlin, Amir Alpert, Steffen Walter, Ali Mohamed, Agathe Bourgogne
  • Patent number: 11395796
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: July 26, 2022
    Assignee: Debiopharm International, S.A.
    Inventors: Angela Romanelli, Rodrigo R. Ruiz-Soto, Jose Ponte, Jutta Deckert, Jan Pinkas
  • Patent number: 11344605
    Abstract: The present invention relates to the use of inhibitors of T cell costimulation and/or activation and/or function in the treatment and/or prevention of cardiac pathologies, in particular heart failure diseases, and/or of related symptoms.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: May 31, 2022
    Assignee: Humanitas Mirasole S.p.A.
    Inventors: Marinos Kallikourdis, Gianluigi Condorelli
  • Patent number: 11304989
    Abstract: Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: April 19, 2022
    Inventors: Raymond Kaempfer, Gila Arad
  • Patent number: 11286306
    Abstract: Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill cancer cells that express TLR9 on their surface. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a TLR9-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: March 29, 2022
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Daniel Abate-Daga, Alan F. List, Sheng Wei
  • Patent number: 11248060
    Abstract: Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 15, 2022
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 11242394
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: February 8, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • Patent number: 11242401
    Abstract: The present invention relates to compositions and methods useful for the treatment of lupus using a humanized IgG1 anti-CD6 monoclonal antibody (T1h) that binds to the SRCR domain 1 (D1) of CD6 without blocking the interaction of CD6 with the CD6 ligand Activated Leukocyte Cell Adhesion Molecule (ALCAM).
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: February 8, 2022
    Inventors: Pradip Nair, Ravindra Belavinakodige Sadashivarao, Ramakrishnan Melarkode
  • Patent number: 11236158
    Abstract: The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or alleviating a symptom associated with elevated IFN-? levels.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 1, 2022
    Assignee: Swedish Orphan Biovitrum AG
    Inventors: Cristina De Min, Walter Ferlin, Fabrizio De Benedetti
  • Patent number: 11207393
    Abstract: The present invention is based, in part, on the identification of methods of modulating PD-1 expression and/or activity in regulatory T cells (Tregs) to thereby regulate effector immune responses in effector T cells (Teffs).
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: December 28, 2021
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Arlene H. Sharpe, Gordon J. Freeman, Loise M. Francisco, Peter T. Sage, Sun J. Lee, Scott B. Lovitch, Vikram R. Juneja, Catherine L. Tan
  • Patent number: 11203644
    Abstract: The present invention provides a novel antibody targeting TLR9.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: December 21, 2021
    Assignee: The University of Tokyo
    Inventors: Kensuke Miyake, Yusuke Murakami, Ryutaro Fukui
  • Patent number: 11202827
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: December 21, 2021
    Assignee: Seagen Inc.
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord, Thomas John Manley
  • Patent number: 11180558
    Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: November 23, 2021
    Assignee: Affimed GMBH
    Inventors: Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch, Stefan Knackmuss, Erich Rajkovic, Martin Treder
  • Patent number: 11168137
    Abstract: Disclosed is a means for reducing side effects of an immune checkpoint regulator that is used as an anticancer drug or the like. A side-effect reducing agent according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. The anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The immune checkpoint regulator may be, for example, an anti-PD-L1 antibody, an antagonistic anti-CTLA-4 antibody, or an agonistic anti-OX40 antibody.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: November 9, 2021
    Inventors: Satoru Ito, Shoji Yokochi, Kouji Matsushima, Satoshi Ueha, Yoshiro Ishiwata
  • Patent number: 11130811
    Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO: 1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 28, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Yao-Bin Liu, Patrick Mayes, Radha Shah Parmar
  • Patent number: 11129881
    Abstract: The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: September 28, 2021
    Inventors: Lonnie D. Shea, Stephen D. Miller, Jonathan Woon Teck Yap, Daniel R. Getts, Derrick McCarthy
  • Patent number: 11130783
    Abstract: The present disclosure is related to compositions comprising peptides that bind CD40 and methods of use in inhibiting interaction of CD40 and CD154 and inducing immunosuppression. Provided herein are methods of transplantation and methods of inhibiting donor specific immune response. Also provided herein are methods of treatment for autoimmune diseases, inflammatory diseases and cancer.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 28, 2021
    Assignees: Regents of the University of Minnesota, Diabetes-Free, Inc.
    Inventors: Bernhard J. Hering, Sabarinathan Ramachandran, Prashant Girinath
  • Patent number: 11117976
    Abstract: The present application discloses a previously unknown function of CD24 expressed on a subset of dendritic cells. The invention encompasses regulating CD24 on these cells to regulate erythropoiesis, induce EPO production and levels, increase RBC levels, and to treat, for example, stress-mediated erythropoiesis. The compositions and methods of the invention are useful, for example, in treating anemia.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: September 14, 2021
    Assignee: University of Virginia Patent Foundation
    Inventors: Thomas J. Braciale, Taeg S. Kim
  • Patent number: 11098131
    Abstract: Provided herein are antibodies that selectively bind to EpCAM and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: August 24, 2021
    Inventors: Ryan Stafford, Alice Yam, John Lee, Stephanie Armstrong, Aaron Sato
  • Patent number: 11077199
    Abstract: The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 3, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Kelly Dare Moynihan, Rebecca Lynn Holden, Darrell J. Irvine, Bradley Lether Pentelute
  • Patent number: 11078518
    Abstract: Various methods for evaluating hemostatic effect and various blood coagulation initiation reagents were studied to construct a method for evaluating blood coagulation reaction mediated by a substance having an activity of substituting for coagulation factor VIII (FVIII). As a result, it was discovered that by using a coagulation initiation reagent containing activated coagulation factor XI (FXIa) and phospholipids, the effect of a substance having an activity of substituting for coagulation factor VIII (FVIII) on blood coagulation reaction can be evaluated using the amount of thrombin generated in the blood sample as an indicator.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: August 3, 2021
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Public University Corporation Nara Medical University
    Inventors: Tetsuhiro Soeda, Takehisa Kitazawa, Midori Shima
  • Patent number: 11072779
    Abstract: The invention relates to a new method for in vitro expansion of CD4+CD25HighCD127?/LOWfoxP3+Tregs, wherein the process of Treg expansion takes place permanently or temporarily at a temperature below 37° C., optimally at a temperature of 33° C., the isolated Tregs are expanded in SCGM or X-vivo-20 medium supplemented with human serum or with foetal bovine serum, and magnetic beads coated with anti-CD3 and anti-CD28 antibodies at 1:1 (cell:bead) ratio and interleukin-2 are added to the culture.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: July 27, 2021
    Inventors: Natalia Marek-Trzonkowska, Piotr Trzonkowski, Malgorzata Mysliwiec
  • Patent number: 11066473
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 20, 2021
    Assignees: argenx IIP BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Patent number: 11040067
    Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to a recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: June 22, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel Strober, Robert Lowsky
  • Patent number: 10981992
    Abstract: The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: April 20, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon
  • Patent number: 10919953
    Abstract: An objective of the present invention is to provide an Fc region variant with enhanced Fc?RIIb-binding activity, and/or enhanced binding selectivity to Fc?RIIb compared to Fc?RIIa (type R), as compared to those of a polypeptide containing an Fe region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing Fc?RIIb-binding activity and also enhancing binding selectivity to Fc?RIIb compared to Fc?RIIa (type R).
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: February 16, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hitoshi Katada, Shojiro Kadono, Futa Mimoto, Tomoyuki Igawa
  • Patent number: 10882916
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 5, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • Patent number: 10876161
    Abstract: The present invention encompasses methods and kits employing pattern recognition receptor expression as a measure of systemic health in a subject afflicted with an oral health condition. In particular, the present invention is directed to methods involving measurement of the expression levels of one or more Pattern Recognition Receptors including but not limited to Toll Like Receptors, myeloid differentiation primary response gene 88 (MyD88), and Nucleotide Binding oligomerization domain containing protein 1 (NOD1), in a companion animal, e.g., a dog or a cat, afflicted with an oral health condition. The described methods enable evaluation of the systemic health of the animal afflicted with an oral health condition by measuring expression levels of the indicated genes as compared to suitable controls.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: December 29, 2020
    Assignee: Hills Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Dale S. Scherl
  • Patent number: 10837060
    Abstract: The invention relates to methods and materials for diagnosing an autoimmune disease such as SLE, Type 1 diabetes, and the like. More particularly, the invention relates to methods and materials for assessing the frequency of recombination sequence (RS) rearrangement as a novel marker for an autoimmune disease. Such an assay can allow clinicians to diagnose an autoimmune disease based on the RS rearrangement frequency in an autoimmune patient as compared to an otherwise healthy control. In addition, the method includes identifying individuals who are at increased risk of developing autoimmunity. The method may also be helpful in directing the type of therapy and monitoring the effects of therapy in patients with autoimmune or non-autoimmune conditions.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: November 17, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Anil K. Panigrahi, Eline Luning Prak
  • Patent number: 10829522
    Abstract: A peptide capable of preventing pathogenic bacteria from colonizing in digestive organs comprises a first domain having an amino acid sequence capable of binding to a minor pilin of IVb fimbriae, and a second domain having an amino acid sequence capable of multimerization, the second domain connect to the first domain via a linker sequence.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: November 10, 2020
    Inventors: Shota Nakamura, Kazuki Kawahara, Hiroya Oki, Takuya Yoshida, Tadayasu Ohkubo, Yuji Kobayashi, Takahiro Maruno, Daisuke Motooka, Shigeaki Matsuda, Toshio Kodama, Tetsuya Iida, Yasumitsu Tsujino, Shunsuke Fukakusa
  • Patent number: 10828354
    Abstract: A vaccine preparation comprising an antigen for use in the prophylactic or therapeutic treatment of a subject by intradermal administration through laser-generated micropores, wherein the antigen is linked to a binder of a dermal migratory antigen-presenting cell (APC); and a pharmaceutical preparation comprising an active substance for use in the prophylactic or therapeutic treatment of a subject by intradermal administration through laser-generated micropores, for regional delivery to a target location. The invention further relates to the laser-assisted intradermal administration of antigens accompanied by repeated chemotherapy.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: November 10, 2020
    Inventors: Reinhard Braun, Dorothea Terhorst, Sandrine Henri, Bernard Malissen, Yoan J. Machado, Mellissa Mayr, Theresa Thalhamer, Veronika Höpflinger, Josef Thalhamer, Richard Weiss
  • Patent number: 10809264
    Abstract: A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: October 20, 2020
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Pugia, Julia Philip, Karen Marfurt
  • Patent number: 10800821
    Abstract: The present invention provides a recombinant fusion protein containing a first extracellular Ig-like domain of a signal-regulator protein alpha (SIRP?), linked to an Fc fragment of a human IgG1. The present invention also provides a polynucleotide encoding the recombinant fusion protein, an expression vector containing the polynucleotide, a method for producing the recombinant protein and a method for treating a disease caused by over expression of CD47.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: October 13, 2020
    Inventors: Wenzhi Tian, Deqiang Jing
  • Patent number: 10793575
    Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: October 6, 2020
    Inventors: Wataru Kawahata, Takao Kiyoi, Takayuki Irie, Tokiko Asami, Masaaki Sawa, Shigeki Kashimoto
  • Patent number: 10752902
    Abstract: The disclosure relates to, among other things, agents that modulate the homophilic interaction between two CRACC polypeptides, methods for making such agents, and therapeutic applications in which the agents are useful. For example, the agents described herein are useful for modulating an immune response in a mammal. Also featured are screening methods for identifying additional agents capable of modulating the activation of an immune cell exposed to an antigen.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: August 25, 2020
    Assignee: Board of Trustees of Michigan State University
    Inventors: Andrea Amalfitano, Yasser A. Aldhamen
  • Patent number: 10695426
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and an Anaplastic Lymphoma Kinase (ALK) inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that test positive for ALK, PD-L 1, or both ALK and PD-L 1.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: June 30, 2020
    Assignees: Pfizer Inc., Merck Sharp & Dohme Corp.
    Inventors: Leena Das-Young, Keith David Wilner, Steffan Nicholas Ho
  • Patent number: 10689444
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 23, 2020
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Patent number: 10688186
    Abstract: This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: June 23, 2020
    Assignee: Tiziana Life Sciences PLC
    Inventor: Kunwar Shailubhai
  • Patent number: 10647770
    Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: May 12, 2020
    Inventors: Shiro Shibayama, Masamichi Imai
  • Patent number: 10640567
    Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10?10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: May 5, 2020
    Inventors: Peter Bo Joakim Ellmark, Eva Maria Dahlen
  • Patent number: 10633450
    Abstract: Methods are provided to enhance the efficacy of antibody therapy directed to tumor cells.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 28, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Holbrook Kohrt, Roch Houot, Ronald Levy, Arash Ash Alizadeh, Matthew J. Goldstein, James Torchia
  • Patent number: 10624950
    Abstract: This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, e.g., to treat disease caused by asthma and chronic inflammation, such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein can inhibit CD8 T cell-mediated cellular immune responses and can, for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 21, 2020
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Vadim Deyev, Robert Levy
  • Patent number: 10610582
    Abstract: A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. a vaccine component, and an agent which enhances the effect of photochemical internalization (PCI)-mediated vaccination is disclosed wherein the agent is a ligand for a Toll-like receptor (TLR), and irradiation is with light of a wavelength effective to activate the photosensitizing agent. Antigenic, e.g. vaccine compositions, useful in such a method are also disclosed along with a method of generating antigen presenting cells which may be used to generate an immune response based on introducing antigenic molecules, e.g. vaccine components, into cells to achieve antigen presentation. The invention also provides methods of achieving vaccination in a subject using such cells.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 7, 2020
    Assignee: PCI BIOTECH AS
    Inventors: Anders Hogset, Pal Johansen
  • Patent number: RE49240
    Abstract: The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: October 11, 2022
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Teru Hideshima, Kenneth C. Anderson, Stephen J. Haggarty, Balaram Ghosh